益气化痰方联合TP方案对晚期非小细胞肺癌患者的临床疗效

目的探讨益气化痰方联合多西他赛和顺铂(TP方案)对晚期非小细胞肺癌患者的临床疗效。方法 104例患者随机分为对照组和观察组,每组52例,对照组给予TP方案,观察组在对照组基础上加用益气化痰方,疗程21 d。然后,检测临床疗效、免疫功能指标(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+、NK细胞)、血清ANGPTL2及CYFRA21-1水平、KPS评分、无进展生存期、总生存期、不良反应发生率变化。结果与对照组比较,观察组总有效率、CD3^+、CD4^+、CD4^+/CD8^+、NK细胞、KPS评分显著升高(P<0.05),CD8^+,ANGPTL2、CYFRA21-1水平,骨髓抑制、肝功能损伤发生率显著降低(P<0.05),无进展生成期显著延长(P<0.05)。结论益气化痰方联合TP方案可有效改善晚期非小细胞肺癌患者免疫损伤,提高机体免疫功能和生存质量,减少不良反应。

Clinical effects of Yiqi Huatan Decoction combined with TP regimen on patients with advanced non-small cell lung cancer

AIM To explore the clinical effects of Yiqi Huatan Decoction combined with docetaxel and cisplatin(TP regimen) on patients with advanced non-small cell lung cancer.METHODS One hundred and four patients were randomly divided into control group(52 cases) for 21-day TP regimen intervention, and observation group(52 cases) for 21-day Yiqi Huatan Decoction and TP regimen administration. Subsequently, the changes in clinical efficacy, immune function indices(CD3^+, CD4^+, CD8^+, CD4^+/CD8^+, NK cell), serum ANGPTL2 and CYFRA21-1 levels, KPS score, progression-free survival, overall survival and occurrence rate of adverse reactions were detected.RESULTS Compared with the control group, the observation group demonstrated significantly increased total effective rate, CD3^+, CD4^+, CD4^+/CD8^+, NK cell, KPS score(P<0.05), markedly decreased CD8^+, ANGPTL2 and CYFRA21-1 levels, occurance rates of bone marrow inhibition and liver function impairment(P<0.05), and obviously prolonged progression-free survival(P<0.05).CONCLUSION For the patients with advanced non-small cell lung cancer, Yiqi Huatan Decoction combined with TP regimen can effectively improve immune damage, enhance body immune functions and life quality, and reduce adverse reactions.